Cargando…

Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long‐term extension studies over 7 years

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We characterized tofacitinib efficacy/safety in Indian vs rest of the world (ROW; excluding India) RA patients. METHODS: Efficacy data were pooled for disease‐modified antirheumatic drug (DMARD)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chopra, Arvind, Shobha, Vineeta, Chandrashekara, Srikantiah, Veeravalli, Sarath C. M., Sharma, Reena, Rao, Uppuluri R., Pandya, Sapan, Wagh, Shrikant, Kadel, Jugal K., Thorat, Amit V., Adhav, Charles, Santos Estrella, Paul, Yu, Wei, Kwok, Kenneth, Wouters, Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496174/ https://www.ncbi.nlm.nih.gov/pubmed/32478474 http://dx.doi.org/10.1111/1756-185X.13853

Ejemplares similares

Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials
por: Citera, Gustavo, et al.
Publicado: (2021)

Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
por: Ciurea, Adrian, et al.
Publicado: (2023)

Timing of tofacitinib therapy is critical to improving outcomes in severe-critical COVID-19 infection: A retrospective study from a tertiary care hospital
por: Kodali, Ramya, et al.
Publicado: (2022)

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
por: Tesser, John, et al.
Publicado: (2023)

Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
por: Ritchlin, Christopher T., et al.
Publicado: (2020)

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
por: Strand, Vibeke, et al.
Publicado: (2018)

Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset
por: Chebbi, Pramod, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia‐Pacific region: Post‐hoc analyses of pooled clinical study data
por: Lee, Eun Bong, et al.
Publicado: (2019)

Tofacitinib
Publicado: (2012)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
por: Mueller, Ruediger B., et al.
Publicado: (2022)

Erratum to Tofacitinib
Publicado: (2012)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects
por: Shin, Wonsuk, et al.
Publicado: (2020)

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
por: Maslennikov, Roman, et al.
Publicado: (2021)

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials
por: Kivitz, Alan J., et al.
Publicado: (2021)

Tofacitinib is not a biologic
por: Marren, Amy S.
Publicado: (2017)

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials
por: Strand, Vibeke, et al.
Publicado: (2018)

Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program
por: Chiorean, Michael, et al.
Publicado: (2023)

Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
por: Inanc, Nevsun, et al.
Publicado: (2023)

Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
por: Karpouzas, George A., et al.
Publicado: (2023)

Tofacitinib for refractory uveitis and scleritis
por: Paley, Michael A., et al.
Publicado: (2018)

Treatment of Multiorgan Sarcoidosis With Tofacitinib
por: Damsky, William, et al.
Publicado: (2020)

Tofacitinib in Hypertrophic Lichen Planus
por: SEIRINGER, Peter, et al.
Publicado: (2020)

Treatment of granuloma annulare with tofacitinib
por: Bosch‐Amate, Xavier, et al.
Publicado: (2022)

A Comparative Study of Shift Work Effects and Injuries among Nurses Working in Rotating Night and Day Shifts in a Tertiary Care Hospital of North India
por: Verma, Anjana, et al.
Publicado: (2018)

Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials
por: Rendas-Baum, Regina, et al.
Publicado: (2017)

The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials
por: Bartlett, Susan J., et al.
Publicado: (2022)

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
por: Eder, Lihi, et al.
Publicado: (2023)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Presence of risk factors associated with colectomy among patients with ulcerative colitis: a post hoc analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program
por: Rubin, David T., et al.
Publicado: (2023)

The Role of Tofacitinib in the Management of Alopecia Totalis
por: Hernandez-Montoya, Carlos, et al.
Publicado: (2019)

Tofacitinib in patients with refractory Takayasu’s arteritis
por: Li, Jing, et al.
Publicado: (2020)

Topical tofacitinib in treatment of alopecia areata
por: Ferreira, Sineida Berbert, et al.
Publicado: (2020)

Effects of naringenin on the pharmacokinetics of tofacitinib in rats
por: Wang, Bo, et al.
Publicado: (2020)

Tofacitinib in Vogt-Koyanagi-Harada disease
por: Dutta Majumder, Parthopratim, et al.
Publicado: (2020)

Granulomatöse rosazeaartiges Exanthem unter Tofacitinib
por: Neumann, Kristina, et al.
Publicado: (2021)

Treatment of Resistant Alopecia areata with Tofacitinib
por: Avhad, Ganesh
Publicado: (2022)

Tofacitinib for the Treatment of Steroid-Induced Rosacea
por: Li, Tianhao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kl176ard77cskgp21g61ul6u2p